Journal
HUMAN IMMUNOLOGY
Volume 70, Issue 10, Pages 854-857Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2009.07.004
Keywords
Multiple myeloma; Monoclonal gammopathy of undetermined significance; CD95; HLA; MICA/B
Categories
Funding
- Fondo de Investigaciones Sanitarias
- Red Genomica del Cancer [06/0020]
- Plan Andaluz de Investigacion [CTS 143]
- Consejeria Andaluz de Salud
- Proyecto de Excelencia de Consejeria de Innovacion [CTS 695]
- Proyecto de investigacion I + D [SAF 2007-63262]
- Integrated European Cancer Immunotherapy [OJ2004/C158, 518234]
Ask authors/readers for more resources
The molecular basis of monoclonal gammopathy of undetermined significance (MGUS) progression to a malignant monoclonal gammopathy remains poorly understood. It was recently suggested that this process involves the suppression of innate and adaptive immunity. In this study, we examined immunogenic differences in bone marrow plasma cells among individuals without gammopathy (controls) and patients with MGUS, multiple myeloma (MM), and plasma cell leukemia. We detected differences in major histocompatibility complex (MHC) class I expression, MHC class I chain-related molecule A, and CD95 that were more evident between MGUS and MM samples: there appeared to be a critical imbalance between natural killer (NK)-cell activating and inhibitory signals during the transition from MGUS to MM. Our results indicate that the human leukocyte antigen (HLA) class I-bright, MICA(dim/-), and CD95(dim/-) immunophenotype reported in myeloma cells may result from an extensive interaction of malignant cells with cytotoxic T and NK cells and appears to be immunoedited for the evasion of immunosurveillance. (C) 2009 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available